These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34367648)

  • 41. Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States.
    Chang SH; Merzkani M; Lentine KL; Wang M; Axelrod DA; Anwar S; Schnitzler MA; Wellen J; Chapman WC; Alhamad T
    Clin J Am Soc Nephrol; 2021 Feb; 16(2):251-261. PubMed ID: 33451990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Donor hepatitis C antibody positivity misclassifies kidney donor profile index in non-hepatitis C-infected donors: time to revise the kidney donor profile index - a retrospective cohort study.
    Yazawa M; Balaraman V; Tsujita M; Azhar A; Talwar M; Bhalla A; Potukuchi PK; Eason JD; Kovesdy CP; Molnar MZ
    Transpl Int; 2020 Dec; 33(12):1732-1744. PubMed ID: 32935416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Kidney transplant from HCV viremic donors to HCV-negative recipients and risk for de novo donor specific antibodies and acute rejection.
    Daloul R; Sureshkumar K; Schnelle K; Von Stein L; Logan A; Pesavento T
    Clin Transplant; 2023 Feb; 37(2):e14895. PubMed ID: 36580971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of using hepatitis c virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate.
    Gernhofer YK; Brambatti M; Greenberg BH; Adler E; Aslam S; Pretorius V
    J Heart Lung Transplant; 2019 Nov; 38(11):1178-1188. PubMed ID: 31492607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Recipient Hepatitis C Status on Outcomes of Deceased Donor Kidney Transplantation.
    Yuan Q; Hong S; Perez-Ortiz A; Roth E; Chang DC; Madsen JC; Elias N
    J Am Coll Surg; 2020 Jun; 230(6):853-861.e3. PubMed ID: 32035979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of Hepatitis C Virus Antibody-Positive Donor Livers in Hepatitis C Nonviremic Liver Transplant Recipients.
    Luckett K; Kaiser TE; Bari K; Safdar K; Schoech MR; Apewokin S; Diwan TS; Cuffy MC; Anwar N; Shah SA
    J Am Coll Surg; 2019 Apr; 228(4):560-567. PubMed ID: 30586641
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors.
    Smith DE; Chen S; Fargnoli A; Lewis T; Galloway AC; Kon ZN; Moazami N
    Semin Thorac Cardiovasc Surg; 2021; 33(2):407-415. PubMed ID: 32621962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome.
    Nair SP; Marella HK; Maliakkal B; Snyder H; Handley C; Kothadia JP; Ali B; Satapathy SK; Molnar MZ; Clark I; Jain R; Helmick R; Eymard C; Eason JD
    Clin Transplant; 2021 May; 35(5):e14281. PubMed ID: 33690929
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial.
    Sise ME; Goldberg DS; Schaubel DE; Fontana RJ; Kort JJ; Alloway RR; Durand CM; Blumberg EA; Woodle ES; Sherman KE; Brown RS; Friedewald JJ; Desai NM; Sultan ST; Levitsky J; Lee MD; Strohbehn IA; Landis JR; Fernando M; Gustafson JL; Chung RT; Reese PP
    Kidney Int Rep; 2022 Feb; 7(2):241-250. PubMed ID: 35155863
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation.
    Somerville L; Doucette K
    Curr Infect Dis Rep; 2018 May; 20(7):18. PubMed ID: 29789956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir.
    Ramirez-Sanchez C; Kozuch J; Shah MM; Berumen J; Mekeel K; Schnickel G; Taremi M; Golts E; Afshar K; Adler E; Pretorius V; Aslam S
    Open Forum Infect Dis; 2022 Nov; 9(11):ofac550. PubMed ID: 36420058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K; Angus P; Gane E; Kao JH; Mantry PS; Mutimer D; Reddy KR; Tran TT; Hu YB; Gulati A; Krishnan P; Dumas EO; Porcalla A; Shulman NS; Liu W; Samanta S; Trinh R; Forns X
    Hepatology; 2018 Oct; 68(4):1298-1307. PubMed ID: 29672891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early initiation of glecaprevir/pibrentasvir after transplantation of HCV-viremic kidneys into HCV-negative recipients is associated with normalization in the altered inflammatory milieu.
    Kim MH; Sise ME; Xu M; Goldberg DS; Fontana RJ; Kort JJ; Alloway RR; Durand CM; Brown RS; Levitsky J; Gustafson JL; Reese PP; Chung RT
    Clin Transplant; 2023 Apr; 37(4):e14926. PubMed ID: 36752566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients.
    Gupta G; Yakubu I; Bhati CS; Zhang Y; Kang L; Patterson JA; Andrews-Joseph A; Alam A; Ferreira-Gonzalez A; Kumar D; Moinuddin IK; Kamal L; King AL; Levy M; Sharma A; Cotterell A; Reichman TW; Khan A; Kimball P; Stiltner R; Baldecchi M; Brigle N; Gehr T; Sterling RK
    Am J Transplant; 2020 Mar; 20(3):739-751. PubMed ID: 31652392
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
    Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
    Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation.
    Sise ME; Strohbehn IA; Chute DF; Gustafson J; Van Deerlin VM; Smith JR; Gentile C; Wojciechowski D; Williams WW; Elias N; Chung RT
    Kidney Int Rep; 2020 Apr; 5(4):459-467. PubMed ID: 32280841
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study.
    Crismale JF; Khalid M; Bhansali A; De Boccardo G; Khaim R; Florman SS; Shapiro R; Schiano TD
    Clin Transplant; 2020 Jan; 34(1):e13761. PubMed ID: 31808193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
    Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
    Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation.
    Hudson MR; Webb AR; Logan AT; Silverman A; Brueckner AJ
    Clin Transplant; 2021 Aug; 35(8):e14386. PubMed ID: 34132438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.